Lifesci Capital upgraded shares of Soleno Therapeutics (NASDAQ:SLNO – Free Report) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports. Lifesci Capital ...

A replay of both events will be available in the Investors section on the Company's website at www.soleno.life.

Choline is an essential nutrient crucial for the development of the brain and nervous system, particularly during pregnancy. Although choline is found in numerous foods, it can be difficult to ...

On Thursday, Baird initiated coverage on Soleno Therapeutics Inc. (NASDAQ:SLNO) with an Outperform rating and set a stock price target of $72.00. The firm believes the potential... REDWOOD CITY, Calif ...

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to 1 platinum-based chemotherapy [ID6403] Medicine Awaiting decision 21 January 2025 ...

Diazoxide choline CR is under clinical development by Soleno Therapeutics and currently in Pre-Registration for Prader-Willi Syndrome (PWS). According to GlobalData, Pre-Registration drugs for ...

Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. Receive News & Ratings ...

Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS). The company attained a significant milestone in fiscal Q3 2024 with the ...

Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS). The company attained a significant milestone in fiscal Q3 2024 with the ...